Although bronchial hyperresponsiveness to cholinergic agents is a main feature of asthma, the role of anticholinergic drugs in chronic asthma management has been largely underestimated.
Tezepelumab reduced the annualised asthma exacerbation rate (AAER) by 86% in a subgroup of people with severe, uncontrolled asthma and polyps in the NAVIGATOR study, topping the 41% reduction ...
Also Read: Amgen/AstraZeneca’s Asthma Drug Tezspire Vs. Sanofi/Regeneron’s Blockbuster Dupixent – Analyst Gives His Pick WAYPOINT is a randomized, double-blind trial that evaluated the ...
Asthma inhalers are hand-held devices that allow you to inhale a dose of medication to treat asthma symptoms. There are many types of asthma inhalers. They differ in whether they're used for quick ...
More than 50% of patients with severe asthma have high eosinophil levels, making them candidates for biologic therapies like Nucala and other drugs like AstraZeneca’s Fasenra (benralizumab ...
AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.